The FDA has signed off on a second COVID-19 booster for over 50’s.
The second booster shot of both the Pfizer-BioNTech and Moderna Covid-19 vaccines was authorized at the end of March without the opinion of an advisory committee of outside experts.
The FDA have said that they didn’t feel the need for outside opinion based on evidence from an Israeli study which showed that a fourth dose was safe among 600,000 people over the age of 60 who received the Pfizer vaccine. The agency lowered the recommended age to include many who are considered high risk in the 50 and up age group.
The study has also shown positive survival benefits and reduced hospitalisations. The FDA has decided not to wait for an Omicron-specific vaccine, as it’s not yet finished. They also haven’t ruled out the possibility of another shot being authorised later in the year.